Partnerships for Development of New Therapeutic Classes for Select Viral and Bacterial Pathogens R01 Federal Grant

Home

RESEARCH

ARTICLES

RESOURCES

Government Jobs
Grant Forums

FAST GRANT SEARCH

FEDERAL GRANTS NEWSLETTER

Partnerships for Development of New Therapeutic Classes for Select Viral and Bacterial Pathogens (R01)

The summary for the Partnerships for Development of New Therapeutic Classes for Select Viral and Bacterial Pathogens (R01) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.

Federal Grant Title:	PARTNERSHIPS FOR DEVELOPMENT OF NEW THERAPEUTIC CLASSES FOR SELECT VIRAL AND BACTERIAL PATHOGENS (R01)
Federal Agency Name:	National Institutes of Health
Program Name:	Microbiology and Infectious Diseases Research
Grant Categories:	Health
CFDA Number:	93.856
Funding Opportunity Number:	RFA-AI-10-010
Posted Date:	May 03, 2010
Creation Date:	May 03, 2010
Original Application Deadline:	Jul 08, 2010
Current Application Deadline:	Jul 08, 2010
Archive Date:	Aug 08, 2010
Total Program Funding:	Information not provided
Maximum Federal Grant Award:	$300,000
Minimum Federal Grant Award:	Information not provided
Expected Number of Awards:	Information not provided
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Grant Description: Purpose. This Funding Opportunity Announcement (FOA) issued by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), invites research applications in support of preclinical development of lead candidate therapeutics against Nesseria gonorrhoeae, Hepatitis B Virus and Clostridium difficile. Mechanism of Support. This FOA will utilize the R01 award mechanism. Funds Available and Anticipated Number of Awards. The NIAID intends to commit $6 million in total costs in FY2011 to fund 6-10 applications in response to this FOA.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/rfa-ai-10-010.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Biomedical Prevention of HIV Research Education (R25); • Partnerships for Next Generation Biodefense Diagnostics (R01); • National Biocontainment Laboratories (NBLs) Operations Support Limited Competition (UC7); • International Extramural Associates Research Development Awards (IEARDA) [G11]; • Non-Antibiotic Selectable Markers for Biodefense (R21); • Partnerships to Improve Diagnosis and Treatment of Selected Drug-Resistant Healthcare-Asso...; • Cooperative Research Partnerships for Biodefense (U01)
More Grants from the National Institutes of Health: • Innovative Approaches and Technologies for Examining the Uncultivable Bacteria of the Oral...; • Research on the Role of Epigenetics in Social, Behavioral, Environmental and Biological Re...; • Pediatric Critical Care and Trauma Scientist Development Program (K12); • Evidence-based Demonstration Projects in Immunization (Admin Supp); • Biomarkers for Diabetes, Digestive, Kidney and Urologic Diseases Using Biosamples from the...